Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.

Pharmacol Rev 2006 Mar;58(1):87-114

Laboratory of Physiological Studies, National Institute on Alcohol Aabuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane MSC 9413, Room 2N-17, Bethesda, Maryland 20892-9413, USA.

The prototypical xanthine oxidase (XO) inhibitor allopurinol, has been the cornerstone of the clinical management of gout and conditions associated with hyperuricemia for several decades. More recent data indicate that XO also plays an important role in various forms of ischemic and other types of tissue and vascular injuries, inflammatory diseases, and chronic heart failure. Allopurinol and its active metabolite oxypurinol showed considerable promise in the treatment of these conditions both in experimental animals and in small-scale human clinical trials. Although some of the beneficial effects of these compounds may be unrelated to the inhibition of the XO, the encouraging findings rekindled significant interest in the development of additional, novel series of XO inhibitors for various therapeutic indications. Here we present a critical overview of the effects of XO inhibitors in various pathophysiological conditions and also review the various emerging therapeutic strategies offered by this approach.

Download full-text PDF

Source
http://dx.doi.org/10.1124/pr.58.1.6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2233605PMC
March 2006
2 Reads

Publication Analysis

Top Keywords

xanthine oxidase
8
animals small-scale
4
experimental animals
4
conditions experimental
4
promise treatment
4
treatment conditions
4
small-scale human
4
human clinical
4
effects compounds
4
beneficial effects
4
trials beneficial
4
clinical trials
4
considerable promise
4
metabolite oxypurinol
4
injuries inflammatory
4
inflammatory diseases
4
vascular injuries
4
tissue vascular
4
types tissue
4
diseases chronic
4

References

(Supplied by CrossRef)

J Heart Lung Transplant 1992

Cardiovasc Res 1985

Can J Cardiol 1999

Hypertension 1999

Biochim Biophys Acta 2001

Br J Pharmacol 1986

Similar Publications